Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 8/2013

01-08-2013 | Original Research Paper

The anti-inflammatory action of Bothrops jararaca snake antithrombin on acute inflammation induced by carrageenan in mice

Authors: Karen de Morais-Zani, Fernanda Peixoto Barbosa Nunes, Jacilene Barbosa da Silva, Márcio José Ferreira, Kathleen Fernandes Grego, Mônica Lopes-Ferreira, Aparecida Sadae Tanaka, Anita Mitico Tanaka-Azevedo

Published in: Inflammation Research | Issue 8/2013

Login to get access

Abstract

Objective and design

Antithrombin is known as the most important natural coagulation inhibitor and has been shown to have anti-inflammatory properties. The present study aimed to investigate the effects of Bothrops jararaca antithrombin on acute inflammation induced by carrageenan in mice.

Methods

We evaluated the anti-inflammatory activity of antithrombin on models of paw edema formation, cell migration and leukocyte–endothelium interaction in mice (Swiss; n = 5). Acute inflammation was induced by the administration of carrageenan (15 mg kg−1).

Results

Treatment with B. jararaca antithrombin (1 mg kg−1) 1 h before or after carrageenan administration significantly inhibited paw edema formation, reduced cell influx to the peritoneal cavity due to reduction in the migration of polymorphonuclear cells, and attenuated leukocyte rolling in the microcirculation of the cremaster muscle.The effects of antithrombin on vascular and cellular events of inflammation were completely abolished by treatment with the cyclo-oxygenase inhibitor indomethacin (4 mg kg−1), suggesting the involvement of prostacyclin in the mechanism of inflammation inhibition by B. jararaca antithrombin.

Conclusion

This work showed for the first time the anti-inflammatory properties of B. jararaca antithrombin on vascular and cellular events of inflammation. These findings suggest that antithrombin is effective in preventing paw edema formation, cell migration and leukocyte rolling induced by carrageenan in mice.
Literature
1.
2.
Bayston TA, Lane DA. Antithrombin: molecular basis of deficiency. Thromb Haemost. 1997;78(1):339–43.PubMed
3.
Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis. 2002;13(8):657–70.PubMedCrossRef
4.
Wiedermann ChJ, Romisch J. The anti-inflammatory actions of antithrombin–a review. Acta Med Austriaca. 2002;29(3):89–92.PubMedCrossRef
5.
6.
Kaneider NC, Reinisch CM, Dunzendorfer S, Romisch J, Wiedermann CJ. Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci. 2002;115(Pt 1):227–36.PubMed
7.
Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 1997;96(7):2302–10.PubMedCrossRef
8.
Zuo XJ, Okada Y, Nicolaidou E, Toyoda T, Marchevsky A, Matloff JM, et al. Antithrombin III inhibits T and B lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Transplant Proc. 1999;31(1–2):847–8. doi:S0041-1345(98)01800-4.PubMedCrossRef
9.
Hoffmann JN, Vollmar B, Romisch J, Inthorn D, Schildberg FW, Menger MD. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med. 2002;30(1):218–25.PubMedCrossRef
10.
Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun. 1989;163(3):1404–11.PubMedCrossRef
11.
Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost. 1998;24(1):27–32.PubMedCrossRef
12.
Dunzendorfer S, Kaneider N, Rabensteiner A, Meierhofer C, Reinisch C, Romisch J, et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood. 2001;97(4):1079–85.PubMedCrossRef
13.
Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol. 1999;19(6):1566–72.PubMedCrossRef
14.
Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost. 1993;69(2):98–102.PubMed
15.
16.
Sun HM, Hong LZ, Shen XK, Lin XQ, Song Y, Shi Y. Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase. Chin Med J (Engl). 2009;122(20):2466–71.
17.
Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock. 1998;10(2):90–6.PubMedCrossRef
18.
Iba T, Kidokoro A, Fukunaga M, Nagakari K, Suda M, Yoshikawa S, et al. Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Med. 2005;31(8):1101–8. doi:10.​1007/​s00134-005-2707-0.PubMedCrossRef
19.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–78. doi:jce10000.PubMedCrossRef
20.
Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34(2):285–92. doi:00003246-200602000-00001.PubMedCrossRef
21.
de Morais KB, Vieira CO, Hirata IY, Tanaka-Azevedo AM. Bothrops jararaca antithrombin: isolation, characterization and comparison with other animal antithrombins. Comp Biochem Physiol B: Biochem Mol Biol. 2009;152(2):171–6.CrossRef
22.
Morais-Zani K, Tanaka AS, Tanaka-Azevedo AM. Isolation of Bothrops jararaca snake antithrombin from the supernatant of fibrinogen purification. J Biomol Tech. 2009;20(5):249–52.PubMed
23.
24.
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76–85.PubMedCrossRef
25.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(259):680–5.PubMedCrossRef
26.
Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996;68(5):850–8.PubMedCrossRef
27.
28.
Rosenfeld G. Symptomatology, pathology and treatment of snake bites in South America. In: Burcherl W, Buckley EE, Deulofeu V, editors. Venomous animals and their venoms. New York: Academic Press; 1971. p. 345–841.
29.
Baez S. An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res. 1973;5(3):384–94.PubMedCrossRef
30.
Lomonte B, Lundgren J, Johansson B, Bagge U. The dynamics of local tissue damage induced by Bothrops asper snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron microscopic study. Toxicon. 1994;32(1):41–55.PubMedCrossRef
31.
32.
Bjork I, Jackson CM, Jornvall H, Lavine KK, Nordling K, Salsgiver WJ. The active site of antithrombin: release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin. J Biol Chem. 1982;257(5):2406–11.PubMed
33.
Vieira CO, Tanaka AS, Sano-Martins IS, Morais KB, Santoro ML, Tanaka-Azevedo AM. Bothrops jararaca fibrinogen and its resistance to hydrolysis evoked by snake venoms. Comp Biochem Physiol B: Biochem Mol Biol. 2008;151(4):428–32.CrossRef
34.
Tanaka-Azevedo AM, Tanaka AS, Sano-Martins IS. A new blood coagulation inhibitor from the snake Bothrops jararaca plasma: isolation and characterization. Biochem Biophys Res Commun. 2003;308(4):706–12.PubMedCrossRef
35.
Tanaka-Azevedo AM, Torquato RJ, Tanaka AS, Sano-Martins IS. Characterization of Bothrops jararaca coagulation inhibitor (BjI) and presence of similar protein in plasma of other animals. Toxicon. 2004;44(3):289–94.PubMedCrossRef
36.
Morais KB, Grego KF, Tanaka-Azevedo AM. Identification of proteins similar to Bothrops jararaca coagulation inhibitor (BjI) in the plasmas of Bothrops alternatus, Bothrops jararacussu and Crotalus durissus terrificus snakes. Comp Biochem Physiol B: Biochem Mol Biol. 2008;149(2):236–40. doi:10.​1016/​j.​cbpb.​2007.​09.​011.CrossRef
37.
38.
Sitonio MM, de Carvalho Junior CH, Campos ID, Silva JB, de Lima MD, Goes AJ, et al. Anti-inflammatory and anti-arthritic activities of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (beta-lapachone). Inflamm Res. 2013;62:107–13. doi:10.​1007/​s00011-012-0557-0.PubMedCrossRef
39.
Henriques MG, Silva PM, Martins MA, Flores CA, Cunha FQ, Assreuy-Filho J et al. Mouse paw edema: a new model for inflammation? Brazilian J Med Biol Res 1987;20(2):243–9.
40.
Chatterjee N, Das S, Bose D, Banerjee S, Chattopadhyay D, Saha KD. Exploring the anti-inflammatory activity of a novel 2-phenylquinazoline analog with protection against inflammatory injury. Toxicol Appl Pharmacol. 2012;264:181–94. doi:10.​1016/​j.​taap.​2012.​07.​032.CrossRef
41.
Meneguzzo DT, Lopes LA, Pallota R, Soares-Ferreira L, Lopes-Martins RA, Ribeiro MS. Prevention and treatment of mice paw edema by near-infrared low-level laser therapy on lymph nodes. Lasers Med Sci. 2012;. doi:10.​1007/​s10103-012-1163-7.PubMed
42.
Rodrigues JA, Vanderlei ES, Silva LM, Araujo IW, Queiroz IN, Paula GA, et al. Antinociceptive and anti-inflammatory activities of a sulfated polysaccharide isolated from the green seaweed Caulerpa cupressoides. Pharm Reports: PR. 2012;64(2):282–92.
43.
44.
Posadas I, Bucci M, Roviezzo F, Rossi A, Parente L, Sautebin L, et al. Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol. 2004;142(2):331–8. doi:10.​1038/​sj.​bjp.​0705650.PubMedCrossRef
45.
Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood. 1999;93(1):157–64.PubMed
46.
47.
Saleh TS, Calixto JB, Medeiros YS. Effects of anti-inflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan. Peptides. 1999;20(8):949–56.PubMedCrossRef
48.
Utsunomiya I, Nagai S, Oh-ishi S. Sequential appearance of IL-1 and IL-6 activities in rat carrageenin-induced pleurisy. J Immunol. 1991;147(6):1803–9.PubMed
49.
Cuzzocrea S, Sautebin L, De Sarro G, Costantino G, Rombola L, Mazzon E, et al. Role of IL-6 in the pleurisy and lung injury caused by carrageenan. J Immunol. 1999;163(9):5094–104.PubMed
50.
Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med. 2001;29(1):134–9.PubMedCrossRef
51.
Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65(5):859–73.PubMedCrossRef
52.
Yamashiro K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Miyamoto K, et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2001;42(7):1553–60.PubMed
53.
Gritti D, Malinverno A, Gasparetto C, Wiedermann CJ, Ricevuti R. Attenuation of leukocyte beta 2-integrin expression by antithrombin-III. Int J Immunopathol Pharmacol. 2004;17(1):27–32.PubMed
54.
Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res. 1990;59(6):895–904.PubMedCrossRef
55.
Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol. 2000;279(1):C98–107.PubMed
Metadata
Title
The anti-inflammatory action of Bothrops jararaca snake antithrombin on acute inflammation induced by carrageenan in mice
Authors
Karen de Morais-Zani
Fernanda Peixoto Barbosa Nunes
Jacilene Barbosa da Silva
Márcio José Ferreira
Kathleen Fernandes Grego
Mônica Lopes-Ferreira
Aparecida Sadae Tanaka
Anita Mitico Tanaka-Azevedo
Publication date
01-08-2013
Publisher
Springer Basel
Published in
Inflammation Research / Issue 8/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-013-0628-x

Other articles of this Issue 8/2013

Inflammation Research 8/2013 Go to the issue

Original Research Paper

Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis

Original Research Paper

Effects of pre- and post-treatment with plant polyphenols on human keratinocyte responses to solar UV

Original Research Paper

Vitamin E protects chondrocytes against hydrogen peroxide-induced oxidative stress in vitro

Original Research Paper

Lack of association between IL-23R gene polymorphisms and systemic lupus erythematosus in a Chinese population

Original Research Paper

Associations of T helper 1, 2, 17 and regulatory T lymphocytes with mortality in severe sepsis

Original Research Paper

Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits